Mode
Text Size
Log in / Sign up

Systematic review details McCune-Albright syndrome prevalence, genetics, and clinical frameworkReview summarizes current understanding of rare McCune-Albright syndrome

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider MAS a rare mosaic disorder caused by somatic GNAS mutations when evaluating compatible clinical presentations.

This systematic review synthesizes existing evidence on McCune-Albright syndrome (MAS), a rare mosaic disorder affecting individuals with the condition. The review aimed to detail the molecular genetic basis, phenotypic heterogeneity, diagnostic strategies, and management approaches for MAS, though it does not report specific study design details, sample size, or follow-up duration from the included studies.

The main findings indicate an estimated prevalence of MAS ranging from 1 in 100,000 to 1 in 1,000,000 individuals, with no clear differences observed across ethnic groups. The pathogenic mechanism is identified as postzygotic somatic gain-of-function mutations in the GNAS gene, which encodes the α subunit of the stimulatory G protein. The identified pathogenic variants are concentrated at codons R201 (e.g., R201H and R201C) and Q227. No specific intervention, comparator, or clinical outcomes were reported in the provided data.

Safety, tolerability, and adverse event data were not reported. Key limitations of the underlying evidence were not specified in the input. The review's practice relevance lies in providing a structured framework to support clinical diagnosis and multidisciplinary management of this complex condition. Clinicians should interpret this as a summary of existing knowledge rather than new primary evidence.

Researchers conducted a systematic review to gather and organize all the existing scientific knowledge about McCune-Albright syndrome (MAS). MAS is a rare genetic condition that affects bone, skin, and hormone-producing tissues. The review looked at studies involving people diagnosed with MAS to understand its causes, how it appears, and how it is managed.

The main finding is that MAS is caused by specific genetic changes, called GNAS mutations, that happen very early in development. These changes are not inherited from parents but occur randomly. The review estimates the condition is very rare, affecting somewhere between 1 in 100,000 and 1 in 1,000,000 individuals, with no clear differences in prevalence across different ethnic groups.

This work did not report on new safety concerns or treatments. The main reason for caution is that this is a review paper. It summarizes and structures what other studies have already found; it is not a new clinical trial or a study that discovered anything novel. Its value is in helping doctors have a clearer framework for diagnosis and coordinating care.

Readers should understand this as a helpful summary of the current medical understanding of a very rare condition. It does not change how MAS is diagnosed or treated today, but it may help guide future research and improve the organization of care for affected individuals and families.

What this means for you:
A review confirms MAS is a rare genetic disorder; it summarizes existing knowledge but does not offer new treatments.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
McCune-Albright syndrome (MAS) is a rare, sporadic mosaic disorder classically characterized by fibrous dysplasia (FD) of bone, café-au-lait macules, and endocrine hyperfunction. The estimated prevalence ranges from 1 in 100,000 to 1 in 1,000,000 individuals, with no clear differences across ethnic groups. The central pathogenic mechanism involves postzygotic somatic gain-of-function mutations in the GNAS gene, which encodes the α subunit of the stimulatory G protein (Gsα). The currently identified pathogenic variants are concentrated at codons R201 (e.g., R201H and R201C) and Q227. This review systematically summarizes the molecular genetic basis, phenotypic heterogeneity, histopathological and imaging characteristics, diagnostic strategies, precision treatment approaches, and long-term prognosis of MAS. By integrating recent advances, we also highlight emerging research directions and provide a structured framework to support clinical diagnosis and multidisciplinary management.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.